Assenagon Asset Management S.A. raised its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 188.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 212,287 shares of the biopharmaceutical company's stock after acquiring an additional 138,685 shares during the quarter. Assenagon Asset Management S.A. owned about 0.28% of Xenon Pharmaceuticals worth $8,358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in XENE. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Xenon Pharmaceuticals during the 1st quarter worth about $17,941,000. Affinity Asset Advisors LLC boosted its position in shares of Xenon Pharmaceuticals by 82.0% in the first quarter. Affinity Asset Advisors LLC now owns 837,387 shares of the biopharmaceutical company's stock valued at $36,050,000 after acquiring an additional 377,387 shares during the period. Logos Global Management LP purchased a new position in Xenon Pharmaceuticals during the second quarter valued at approximately $14,621,000. Ikarian Capital LLC increased its holdings in Xenon Pharmaceuticals by 169.6% during the 1st quarter. Ikarian Capital LLC now owns 107,187 shares of the biopharmaceutical company's stock worth $4,614,000 after acquiring an additional 261,276 shares during the period. Finally, Artal Group S.A. bought a new stake in Xenon Pharmaceuticals during the 1st quarter worth approximately $10,908,000. Hedge funds and other institutional investors own 95.45% of the company's stock.
Xenon Pharmaceuticals Stock Performance
Shares of XENE stock traded up $0.04 on Tuesday, hitting $41.78. 327,139 shares of the company's stock traded hands, compared to its average volume of 387,861. The stock has a market capitalization of $3.15 billion, a price-to-earnings ratio of -15.47 and a beta of 1.25. The company's fifty day simple moving average is $40.44 and its 200 day simple moving average is $40.15. Xenon Pharmaceuticals Inc. has a one year low of $27.99 and a one year high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.05). During the same quarter in the prior year, the company earned ($0.72) earnings per share. As a group, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have commented on XENE shares. HC Wainwright started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 1st. They set a "buy" rating and a $53.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Wedbush cut their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Finally, Needham & Company LLC dropped their target price on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating for the company in a research report on Monday, August 12th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $57.45.
Check Out Our Latest Report on XENE
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
